Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Phase 2 weight outcomes Jastreboff and colleagues randomized 338 adults with a BMI of 30 or above (or 27 or above with a weight-related condition) to retatrutide or placebo for 48 weeks
Standard laboratory handling and personal protective equipment apply
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Ozempic, Rybelsus) and chronic weight management (Wegovy)
Discuss your treatment options with your clinician if you have certain medical conditions or other factors that affect your health, which include: Diabetes, because Wegovy jabs can cause low blood sugar if you have diabetes
Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus
Crucially, it achieves this without altering systemic hormone levels or modifying metabolic pathways, keeping background variable noise completely absent from your laboratory datasets
